Effects of MetAP2 inhibition on hyperphagia and body weight in Prader–Willi syndrome: A randomized, double‐blind, placebo‐controlled trial
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aims: There are no treatments for the extreme hyperphagia and obesity in Prader–Willi syndrome ( PWS ). The bestPWS clinical trial assessed the efficacy, safety and tolerability of the methionine aminopeptidase 2 ( MetAP 2) inhibitor, beloranib. Materials and Methods: Participants with PWS (12‐65 years old) were randomly assigned (1:1:1) to biweekly placebo, 1.8 mg beloranib or 2.4 mg beloranib injection for 26 weeks at 15 US sites. Co‐primary endpoints were the changes in hyperphagia [measured by Hyperphagia Questionnaire for Clinical Trials ( HQ ‐ CT ); possible score 0‐36] and weight by intention‐to‐treat. ClinicalTrials.gov registration: NCT02179151 . Results: One‐hundred and seven participants were included in the intention‐to‐treat analysis: placebo ( n = 34); 1.8 mg beloranib ( n = 36); or 2.4 mg beloranib ( n = 37). Improvement (reduction) in HQ‐CT total score was greater in the 1.8 mg (mean difference −6.3, 95% CI −9.6 to −3.0; P = .0003) and 2.4 mg beloranib groups (−7.0, 95% CI −10.5 to −3.6; P = .0001) vs placebo. Compared with placebo, weight change was greater with 1.8 mg (mean difference − 8.2%, 95% CI −10.8 to −5.6; P < .0001) and 2.4 mg beloranib (−9.5%, 95% CI −12.1 to −6.8; P < .0001). Injection site bruising was the most frequent adverse event with beloranib. Dosing was stopped early due to an imbalance in venous thrombotic events in beloranib‐treated participants (2 fatal events of pulmonary embolism and 2 events of deep vein thrombosis) compared with placebo. Conclusions: MetAP2 inhibition with beloranib produced statistically significant and clinically meaningful improvements in hyperphagia‐related behaviours and weight loss in participants with PWS . Although investigation of beloranib has ceased, inhibition of MetAP2 is a novel mechanism for treating hyperphagia and obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 1×
“Reductions in hunger and caloric intake are likely the result of an integrated effect of changes in circulating fatty acids, lipids, adipokines and other peripheral signals on CNS regions that regulate appetite.(39) Whether MetAP2 inhibition normalizes the hyperactivation evident in brain regions that drive eating beh…”
BackgroundEsposito, K., Pontillo, A., Di Palo, C., Giugliano, G., Masella, M., Marfella, R., & Giugliano, D. (2003) · JAMA · doi:10.1001/jama.289.14.1799 · Cited by 1,511 · cited 1×
“The reduction in leptin and increase in adiponectin observed with beloranib treatment are consistent with weight loss and the concomitant decrease in fat mass.(34) The mechanisms for weight loss and improvement in cardiometabolic markers with MetAP2 inhibitors are attributed to 2 primary”
BackgroundCassidy, S. B., Schwartz, S., Miller, J. L., & Driscoll, D. J. (2012) · Genetics in Medicine · doi:10.1038/gim.0b013e31822bead0 · Cited by 1,452
Self-citationAngiogenesis Inhibitor, TNP-470, Prevents Diet-Induced and Genetic Obesity in Mice
Bråkenhielm, E., Cao, R., Gao, B., Angelin, B., Cannon, B., Parini, P., & Cao, Y. (2004) · Circulation Research · doi:10.1161/01.res.0000132745.76882.70 · Cited by 326
Neural Mechanisms Underlying Hyperphagia in Prader‐Willi Syndrome
Holsen, L. M., Zarcone, J. R., Brooks, W. M., Butler, M. G., Thompson, T. I., Ahluwalia, J. S., Nollen, N. L., & Savage, C. R. (2006) · Obesity · doi:10.1038/oby.2006.118 · Cited by 189 · cited 1×
“Whether MetAP2 inhibition normalizes the hyperactivation evident in brain regions that drive eating behaviour that has been observed in patients with PWS remains to be determined.(40) Beloranib has been studied in individuals with obesity, type 2 diabetes and hypothalamic injury-associated obesity.”
BackgroundSelf-citationEfficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial
Kim, D. D., Krishnarajah, J., Lillioja, S., de Looze, F., Marjason, J., Proietto, J., Shakib, S., Stuckey, B. G. A., Vath, J. E., & Hughes, T. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12457 · Cited by 62 · cited 3×
“MetAP2 inhibitors is hypothesized to be due to direct effects on adipose tissue that reduce fat synthesis and increase fat oxidation as well as metabolic and hormonal changes that reduce appetite and food intake, while maintaining basal metabolic rate.(19,21) In prior clinical trials in individuals with obesity (witho…”
BackgroundSelf-citation
Cited by
Prader-Willi Syndrome - Clinical Genetics, Diagnosis and Treatment Approaches: An Update
Butler, M. G., Miller, J. L., & Forster, J. L. (2019) · Current Pediatric Reviews · doi:10.2174/1573396315666190716120925 · Cited by 355
Self-citationTargeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
van Iersel, L., Brokke, K. E., Adan, R. A. H., Bulthuis, L. C. M., van den Akker, E. L. T., & van Santen, H. M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00017 · Cited by 146
Müller, H. L., Tauber, M., Lawson, E. A., Özyurt, J., Bison, B., Martinez-Barbera, J.-P., Puget, S., Merchant, T. E., & van Santen, H. M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00351-z · Cited by 144
Hypothalamic obesity: prologue and promise
Abuzzahab, M. J., Roth, C. L., & Shoemaker, A. H. (2019) · Hormone Research in Paediatrics · doi:10.1159/000496564 · Cited by 71
Self-citationObesity medications in development
Rebello, C. J., & Greenway, F. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1705277 · Cited by 62
Miller, J. L., Gevers, E., Bridges, N., Yanovski, J. A., Salehi, P., Obrynba, K. S., Felner, E. I., Bird, L. M., Shoemaker, A. H., Angulo, M., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad014 · Cited by 55
Self-citationRandomized controlled trial of Tesomet for weight loss in hypothalamic obesity
Huynh, K., Klose, M., Krogsgaard, K., Drejer, J., Byberg, S., Madsbad, S., Magkos, F., Aharaz, A., Edsberg, B., Tfelt-Hansen, J., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-0972 · Cited by 43
Acquired hypothalamic obesity: A clinical overview and update
Roth, C. L., & McCormack, S. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15530 · Cited by 42
“97,98 However, beloranib was withdrawn from clinical trials due to potential increases in thromboembolic events. significant side effects.”
BackgroundMultidisciplinary Approach for Hypothalamic Obesity in Children and Adolescents: A Preliminary Study
Tessaris, D., Matarazzo, P., Tuli, G., Tuscano, A., Rabbone, I., Spinardi, A., Lezo, A., Fenocchio, G., Buganza, R., & de Sanctis, L. (2021) · Children · doi:10.3390/children8070531 · Cited by 11
“Studies on the administration of glucagon-like peptide-1 receptor agonist (GLP-1 RA) have shown varying degrees of success [25,26], while methionine aminopeptidase 2 [27] was successful in lowering body weight, but dosing was discontinued early due to venous thrombotic events.”
Background
Metadata
- Authors
- McCandless, S. E., Yanovski, J. A., Miller, J., Fu, C., Bird, L. M., Salehi, P., Chan, C. L., Stafford, D., Abuzzahab, M. J., Viskochil, D., Barlow, S. E., Angulo, M., Myers, S. E., Whitman, B. Y., Styne, D., Roof, E., Dykens, E. M., Scheimann, A. O., Malloy, J., Zhuang, D., Taylor, K., Hughes, T. E., Kim, D. D., & Butler, M. G.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-07-13
- Volume
- 19
- Issue
- 12
- Pages
- 1751-1761
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2618318751
- Cited by
- 108
- References
- 7
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.